Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Life is complicated: so is apoCIII.

Reyes-Soffer G, Ginsberg HN.

J Lipid Res. 2019 Aug;60(8):1347-1349. doi: 10.1194/jlr.C119000214. Epub 2019 Jun 25. No abstract available.

PMID:
31239286
2.

Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.

Reyes-Soffer G, Sztalryd C, Horenstein RB, Holleran S, Matveyenko A, Thomas T, Nandakumar R, Ngai C, Karmally W, Ginsberg HN, Ramakrishnan R, Pollin TI.

Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):63-72. doi: 10.1161/ATVBAHA.118.311476.

PMID:
30580564
3.

Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects.

Nandakumar R, Matveyenko A, Thomas T, Pavlyha M, Ngai C, Holleran S, Ramakrishnan R, Ginsberg HN, Karmally W, Marcovina SM, Reyes-Soffer G.

J Lipid Res. 2018 Dec;59(12):2397-2402. doi: 10.1194/jlr.P082834. Epub 2018 Oct 7.

PMID:
30293969
4.

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L.

J Am Coll Cardiol. 2018 Jan 16;71(2):177-192. doi: 10.1016/j.jacc.2017.11.014. Review.

5.

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.

Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y, Jumes P, Wagner JA, Hubbard B, Previs SF, Roddy T, Johnson-Levonas AO, Gutstein DE, Marcovina SM, Rader DJ, Ginsberg HN, Millar JS, Reyes-Soffer G.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1770-1775. doi: 10.1161/ATVBAHA.117.309549. Epub 2017 Jul 20.

6.

The metabolism of lipoprotein (a): an ever-evolving story.

Reyes-Soffer G, Ginsberg HN, Ramakrishnan R.

J Lipid Res. 2017 Sep;58(9):1756-1764. doi: 10.1194/jlr.R077693. Epub 2017 Jul 18. Review.

7.

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.

Millar JS, Lassman ME, Thomas T, Ramakrishnan R, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Wagner JA, Holleran S, Obunike J, Liu Y, Aoujil S, Standiford T, Gutstein DE, Ginsberg HN, Rader DJ, Reyes-Soffer G.

J Lipid Res. 2017 Jun;58(6):1214-1220. doi: 10.1194/jlr.M074880. Epub 2017 Mar 17.

8.

Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.

Khavandi M, Duarte F, Ginsberg HN, Reyes-Soffer G.

Curr Cardiol Rep. 2017 Jan;19(1):7. doi: 10.1007/s11886-017-0818-1. Review.

9.

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.

Circulation. 2017 Jan 24;135(4):352-362. doi: 10.1161/CIRCULATIONAHA.116.025253. Epub 2016 Dec 16.

10.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Pollan L, Tohyama J, Johnson-Levonas AO, Wagner JA, Holleran S, Obunike J, Liu Y, Ramakrishnan R, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ.

J Clin Invest. 2016 Apr 1;126(4):1603-4. doi: 10.1172/JCI87364. Epub 2016 Apr 1. No abstract available.

11.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.

Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN.

Arterioscler Thromb Vasc Biol. 2016 May;36(5):994-1002. doi: 10.1161/ATVBAHA.115.306680. Epub 2016 Mar 10. Erratum in: Arterioscler Thromb Vasc Biol. 2016 May;36(5):e51.

12.

Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.

Reyes-Soffer G, Moon B, Hernandez-Ono A, Dionizovik-Dimanovski M, Jimenez J, Obunike J, Thomas T, Ngai C, Fontanez N, Donovan DS, Karmally W, Holleran S, Ramakrishnan R, Mittleman RS, Ginsberg HN.

Sci Transl Med. 2016 Jan 27;8(323):323ra12. doi: 10.1126/scitranslmed.aad2195. Erratum in: Sci Transl Med. 2016 Feb 10;8(325):325er3. Dionizovick-Dimanovski, Marija [corrected to Dionizovik-Dimanovski, Marija].

13.

Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.

Ronsein GE, Reyes-Soffer G, He Y, Oda M, Ginsberg H, Heinecke JW.

Mol Cell Proteomics. 2016 Mar;15(3):1083-93. doi: 10.1074/mcp.M115.054528. Epub 2015 Dec 14.

14.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Pollan L, Tohyama J, Johnson-Levonas AO, Wagner JA, Holleran S, Obunike J, Liu Y, Ramakrishnan R, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ.

J Clin Invest. 2015 Jun;125(6):2510-22. doi: 10.1172/JCI80025. Epub 2015 May 11. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1603-4.

15.

Autophagy and cardiometabolic risk factors.

Juárez-Rojas JG, Reyes-Soffer G, Conlon D, Ginsberg HN.

Rev Endocr Metab Disord. 2014 Dec;15(4):307-15. doi: 10.1007/s11154-014-9295-7. Review.

16.

Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins.

Lassman ME, McAvoy T, Lee AY, Chappell D, Wong O, Zhou H, Reyes-Soffer G, Ginsberg HN, Millar JS, Rader DJ, Gutstein DE, Laterza O.

Clin Chem. 2014 Sep;60(9):1217-24. doi: 10.1373/clinchem.2014.222455. Epub 2014 Apr 21.

17.

Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS.

Pan Y, Zhou H, Mahsut A, Rohm RJ, Berejnaia O, Price O, Chen Y, Castro-Perez J, Lassman ME, McLaren D, Conway J, Jensen KK, Thomas T, Reyes-Soffer G, Ginsberg HN, Gutstein DE, Cleary M, Previs SF, Roddy TP.

J Lipid Res. 2014 Jun;55(6):1179-87. doi: 10.1194/jlr.D047829. Epub 2014 Apr 2.

18.

Niacin: a long history, but a questionable future.

Ginsberg HN, Reyes-Soffer G.

Curr Opin Lipidol. 2013 Dec;24(6):475-9. doi: 10.1097/MOL.0000000000000017. Review.

PMID:
24184940
19.

Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry.

Zhou H, Castro-Perez J, Lassman ME, Thomas T, Li W, McLaughlin T, Dan X, Jumes P, Wagner JA, Gutstein DE, Hubbard BK, Rader DJ, Millar JS, Ginsberg HN, Reyes-Soffer G, Cleary M, Previs SF, Roddy TP.

Rapid Commun Mass Spectrom. 2013 Jun 30;27(12):1294-302. doi: 10.1002/rcm.6572.

20.

Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial.

Reyes-Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, Ginsberg HN.

Diabetes Care. 2013 Feb;36(2):422-8. doi: 10.2337/dc11-2556. Epub 2012 Oct 1.

21.

Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation.

Khan RS, Kato TS, Chokshi A, Chew M, Yu S, Wu C, Singh P, Cheema FH, Takayama H, Harris C, Reyes-Soffer G, Knöll R, Milting H, Naka Y, Mancini D, Schulze PC.

Circ Heart Fail. 2012 May 1;5(3):340-8. doi: 10.1161/CIRCHEARTFAILURE.111.964031. Epub 2012 Feb 29. Erratum in: Circ Heart Fail. 2012 Sep 1;5(5):e91.

22.

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.

Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN.

Expert Opin Pharmacother. 2011 Jun;12(9):1429-38. doi: 10.1517/14656566.2011.563506. Epub 2011 Mar 23. Review.

PMID:
21426238
23.

Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus.

Reyes-Soffer G, Holleran S, Di Tullio MR, Homma S, Boden-Albala B, Ramakrishnan R, Elkind MS, Sacco RL, Ginsberg HN.

Metabolism. 2010 Sep;59(9):1365-71. doi: 10.1016/j.metabol.2009.12.023. Epub 2010 Jan 27.

24.

Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus.

Reyes-Soffer G, Holleran S, Karmally W, Ngai CI, Chen NT, Torres M, Ramakrishnan R, Blaner WS, Berglund L, Ginsberg HN, Tuck C.

J Lipid Res. 2009 Sep;50(9):1901-9. doi: 10.1194/jlr.M900092-JLR200. Epub 2009 May 8.

Supplemental Content

Loading ...
Support Center